Physician profile
Cheng Sun
NPI 1437358892
$3,074.69
in general payments reported to CMS, 2019-2025
14 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $591 · 2022: $818 · 2023: $562 · 2024: $840 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.58 |
| Education | $117.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $700.88 | 2021-2025 | Jakafi |
| Janssen Biotech, INC. | $376.90 | 2021-2024 | Talvey, Tecvayli |
| Sanofi-Aventis U.S. LLC | $246.41 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $240.88 | 2022-2023 | Imbruvica |
| Pfizer INC. | $239.96 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $223.57 | 2024 | |
| Amgen INC. | $215.68 | 2023-2024 | Kyprolis, Blincyto |
| Astellas Pharma US INC | $204.23 | 2021-2024 | Xospata |
| Gilead Sciences, INC. | $139.29 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.42 | 2024 | |
| Daiichi Sankyo INC. | $124.99 | 2022 | |
| Jazz Pharmaceuticals INC. | $116.25 | 2021 | |
| Kite Pharma, INC. | $97.34 | 2024 | |
| Boston Scientific Corporation | $22.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheng Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.